Edaravone (TTYP01)
Small molecule
Evidence outlook · regulatory review
Acute Ischemic Stroke: application under NMPA review
NMPA accepts the marketing application for edaravone tablets (TTYP01) in acute ischemic stroke (Huadong Medicine notice 2025-07-31) (2025-07-31). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
Latest reported trial: NCT06648304 · Phase 3 · met primary endpoint · grade pending
Also in development:Alzheimer's Disease · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06648304 NCT06648304 · Acute Ischemic Stroke Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT06648304 | 3 | Proportion of subjects with mRS score ≤1 on Day 90 of treatment. (90 days after treatment initiation) 2024-06-17 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Acute Ischemic Stroke: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Edaravone (TTYP01): this drug | Phase 3 | Small molecule | oxidative stress | not yet graded | No reviewed efficacy summary in this indication | |
| Ticagrelor (Brilinta) | Approved | Small molecule | P2Y12 receptor | Reliable signal | NCT03354429: Composite of Subsequent Stroke or Death (From randomisation (day 1) to visit 3 (day 30-34)): TICAGRELOR 303 Participants | PLACEBO 362 Participants | |
| Rinvecalinase Alfa | Phase 2/3 | Protein / enzyme therapeutic | Tissue kallikrein-1 (KLK1) | not yet graded | No reviewed efficacy summary in this indication | |
| Apadamtase Alfa (Adzynma) | Phase 2 | Protein / enzyme therapeutic | ADAMTS13 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-4029 | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-7450 | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-8829 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Edaravone (TTYP01) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
October 2028 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent